Background. It is unknown whether serum concentrations of mannan-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) influence the risk of adverse events (AEs) in children with cancer presenting with fever in neutropenia (FN). Methods. Pediatric patients with cancer presenting with FN after non-myeloablative chemotherapy were observed in a prospective multicenter study. Mannan-binding lectin and MASP-2 were measured using commercially available enzyme-linked immunosorbent assay in serum taken at cancer diagnosis. Multiple FN episodes per patient were allowed. Associations of MBL and MASP-2 with AE in general, with bacteremia, and with serious medical complications (SMC) during FN were analyzed using mixed logistic regression. Results. Of 278 FN episodes, AE was reported in 84 (30%), bacteremia was reported in 42 (15%), and SMC was reported in 16 (5.8%). Median MBL was 2152 ng/mL (range, 7-10 060). It was very low (<100) in 11 (9%) patients, low (100-999) in 36 (29%) patients, and normal (1000) in 79 (63%) patients. Median MASP-2 was 410 ng/mL (range, 68-2771). It was low (<200) in 18 (14%) patients and normal in the remaining 108 (86%) patients. Mannan-binding lectin and MASP-2 were not significantly associated with AE or bacteremia. Normal versus low MBL was independently associated with a significantly higher risk of SMC (multivariate odds ratio, 12.8; 95% confidence interval, 1.01-163; P = .050). Conclusions. Mannan-binding lectin and MASP-2 serum concentrations were not found to predict the risk to develop AEs or bacteremia during FN. Normal MBL was associated with an increased risk of SMC during FN. This finding, in line with earlier studies, does not support the concept of MBL supplementation in MBL-deficient children with cancer presenting with FN.
innate immune system have been proposed to explain part of the individual susceptibility to infection in this setting, where cellular mechanisms of immunity are uniformly impaired [4] .
Mannan-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) are the main proteins of the lectin pathway of complement activation, an important component of innate immunity [5] [6] [7] . Upon binding of the MBL-lectin domain to pathogens, phospholipids, nucleic acids, or apoptotic cells, the MBL/MASP-2 complex cleaves C4 and C2, and thereby generates the C3 convertase C2bC4b. Conversion of C3 to C3a and C3b leads to (1) opsonization and direct lysis of pathogens and (2) recruitment of inflammatory cells via the terminal complement pathway [7, 8] . For MBL and MASP-2, which are both synthesized in the liver, large interindividual variations of serum concentrations have been reported in healthy subjects. These variations mainly result from a number of polymorphisms in the MBL2 gene and its promoter on chromosome region 10q11.2 (estimated cumulative gene frequency, approximately 25%) and in the MASP2/Map19 gene on 1p36.2-3 (1.3%-6.3%), respectively [7] [8] [9] [10] . Correspondingly, 30% of apparently healthy persons might be called MBL-deficient, and approximately 5% are MASP-2-deficient, although there is no consensus on the limits of serum concentrations defining such deficiencies [7, 8] .
The results of previous studies have shown that MBL deficiency may predispose children to meningococcal infections and to infections of the upper respiratory tract [11] . However, the impact of MBL deficiency on chemotherapy-related infections in pediatric patients remains controversial: The results of some studies illustrated significant associations between MBL deficiency [12] [13] [14] or MASP-2 deficiency [15] and the risk to develop FN or infections during chemotherapy, whereas others did not [16] [17] [18] . In children who had developed FN, MBL deficiency was not associated with more severe infections in 2 small-to medium-sized prospective studies [19] [20] . One study even reported a lower risk for admission to the pediatric intensive care unit (PICU) in those with MBL deficiency [20] . In a recent meta-analysis, MBL-deficiency was not an independent risk factor for FN or infection in pediatric patients with cancer [21] .
The aim of this study in pediatric patients with cancer presenting with FN was to determine whether serum concentrations of MBL and MASP-2, determined at cancer diagnosis, are associated with the risk to develop any adverse event (AE), bacteremia, or a serious medical complication (SMC) during FN.
PATIENTS AND METHODS

Study Design and Patients
This study is based on information collected in 2 independent multicenter studies on pediatric patients with cancer: First, the prospective SPOG 2003 FN study described risk factors associated with AE and with bacteremia in patients presenting with FN after nonmyeloablative chemotherapy [22, 23] [24, 25] . Both studies had been approved by the local institutional review boards (IRBs). All patients of the prospective study had given informed consent. The retrospective study had received a waiver of informed consent by the IRBs.
Patients included in both studies were identified using 4 patient-related (center, date of birth, initials, sex) and 3 disease-related criteria (date of diagnosis, diagnosis, relapse status). These patients had been diagnosed with cancer up to the age of 18 between 2002 and 2006 in the 4 pediatric oncology centers, and they developed FN after receiving non-myeloablative chemotherapy from 2004 to 2007. For the diagnosis of FN, fever was defined as axillary temperature either 38.5°C once or 38.0°C for 2 hours [1, 22, 23] , and neutropenia was defined as an absolute neutrophil count 0.5 G/L [1] . Multiple FN episodes per patient were allowed.
Management of FN
At presentation with FN, all patients underwent a physical examination, blood cell count including differential leukocyte count, and blood cultures. They were hospitalized and treated with empirical intravenous broadspectrum antimicrobial therapy, covering gram-positive cocci (except methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, enterococci) plus gramnegative bacteria, and adapted to local resistance patterns [23] . The treating physician decided on further diagnostic procedures and supportive measures [22] .
Definition of Outcomes
The first outcome analyzed was AEs, including SMC as a result of infection, microbiologically defined infection, and radiologically confirmed pneumonia [22] . Serious medical complication included death, complications requiring admission to the PICU, and potentially life-threatening complications as judged by the treating physician [26] [27] [28] [29] . Microbiologically defined infections included positive bacterial or fungal culture from a normally sterile body fluid or compartment; and detection of viral antigen or product of polymerase chain reaction by a validated microbiologic method [22] . The second outcome analyzed was bacteremia, defined as at least 1 positive blood culture, irrespective of the pathogen detected, using a qualitative automated culture system (BacT/ALERT, bioMérieux, Geneva, Switzerland; or BACTEC, Becton Dickinson, Basel, Switzerland). Molecular, nonculture-based methods were not used in this study [23] . The third outcome analyzed was SMC as defined above [29] .
Determination of Serum Concentrations of MBL and MASP-2
Remnants of serum taken for clinical purposes at cancer diagnosis, ie, not at presentation with FN, were stored at −20°C until analysis. MBL and MASP-2 concentrations were measured in these sera using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions (MBL oligomer ELISA kit, Antibodyshop, Gentofte, Denmark; MASP-2 ELISA kit HK326, HyCult, Uden, The Netherlands).
There are no established limits defining abnormal versus normal MBL or MASP-2 serum concentrations [8] . For analysis, concentrations were categorized applying limits used earlier for assessing the risk to develop FN during chemotherapy in a different cohort [13, 15] . In particular, 3 categories (very low, low, normal) were used for MBL with limits set at 100 ng/mL and 1000 ng/ mL [13] , and 2 categories (low, normal) were used for MASP-2 with the limit set at 200 ng/mL [15] .
Statistics
Because of non-normally distributed data, median and interquartile ranges (IQRs) were calculated. Exact Fisher's and Fisher-Freeman-Halton tests were used where applicable. Univariate and multivariate mixed logistic regression, with a random intercept per patient to account for multiple episodes per patient, was used for analysis of associations with the binary outcomes [30] . Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated. In multivariate mixed logistic regression, the associations of MBL and MASP-2 were adjusted for the risk factors found to be significantly associated with the respective outcome in the SPOG 2003 FN study [22, 23, 29] .
All exact analyses were performed using StatXact 9.0 (Cytel Software Corp, Cambridge, MA), and all remaining analyses were performed using R 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria). In particular, for mixed logistic regression, the sabre procedure of the sabreR library was used [31] . Two-sided tests were used throughout, and P values <.050 were considered significant.
RESULTS
Patients and Patient Characteristics
For this study, 166 patients with 357 FN episodes were potentially eligible because they had been participants of SPOG 2003 FN diagnosed with cancer up to the end of 2006 in the 4 pediatric oncologic centers of the Universities of Bern, Geneva, Zurich (all Switzerland), and Bonn (Germany). Of these, 126 (76%) patients with 278 episodes of FN could be included in this study. Fifty-six, 9, 48, and 13 patients were recruited in the 4 centers, respectively. The remaining 40 patients with 79 FN episodes were excluded because no serum remnants were assessible for determination of MBL/MASP-2. Patients with solid tumors, including central nervous system tumors, were less likely to be included than those with hematological malignancies, as were patients with relapsed versus non-relapsed cancer ( Table 1) .
Episodes of FN and Outcomes
In 52 of the 126 patients, only 1 FN episode was studied. The median number of FN episodes studied per patient was 2 (IQR, 1-3; range, 1 − 10). An AE was reported in 84 (30%) of the 278 FN episodes, bacteremia was reported in 42 (15%), and SMC was reported in 16 (5.8%). These outcomes were not significantly associated with inclusion versus exclusion (Table 1) . Furthermore, the proportions of episodes with outcomes were comparable with those in the SPOG 2003 FN study (30% vs 29% with AE, P = .43; 15% vs 16% with bacteremia, P = .58; 5.8% vs 5.2% with SMC, P = .66) [22] .
In the 84 episodes with AEs, SMCs were reported in 16 (19%; 3 deaths, 12 life-threatening complications, 13 PICU admissions), microbiologically defined infections were reported in 61 (73%; 42 bacteremia, 6 other bacterial infections, 4 fungal infections, 20 viral infections), and radiologically defined pneumonia was reported in 28 (33%).
Serum Concentrations of MBL and MASP-2
In the 126 patients, the median MBL serum concentration at cancer diagnosis was 2152 ng/mL (IQR, 510−3807; range, 7−10 060). MBL was <100 ng/mL (very low) in 11 (9%) patients with 24 (9%) FN episodes, it was 100−999 ng/mL (low) in 36 (29%) patients with 82 (29%) episodes, and it was 1000 ng/mL (normal) in 79 (63%) patients with 172 (62%) FN episodes.
The median MASP-2 serum concentration was 410 ng/mL (IQR, 263−637; range, 68−2771). MASP-2 was <200 ng/mL (low) in 18 (14%) patients with 36 (13%) FN episodes, and it was 200 ng/mL (normal) in the remaining 108 (86%) patients with 242 (87%) FN episodes.
Association of MBL and MASP-2 With Adverse Events
In univariate analysis, neither MBL nor MASP-2 at cancer diagnosis were significantly associated with the risk to develop AEs during FN. Multivariate analysis, adjusted for 4 characteristics known to be associated with AE (therapy more intensive than maintenance chemotherapy for acute lymphoblastic leukemia, hemoglobin level 90 g/L, leukocyte count <0.3 G/L, platelet count <50 G/L) [22] , confirmed these results ( Table 2) .
Association of MBL and MASP-2 With Bacteremia
In univariate analysis, neither MBL nor MASP-2 at cancer diagnosis were significantly associated with the risk of developing bacteremia during FN. Multivariate analysis, adjusted for 5 characteristics known to be associated with bacteremia (diagnosis of acute myeloid leukemia, bone marrow involvement, temperature at presentation >39.5°C, leukocyte count <0.3 G/L, platelet count <50 G/L) [23] , confirmed these results ( Table 3) .
Association of MBL and MASP-2 With SMCs
In univariate analysis, normal versus low MBL was tendentially associated with an increased risk of developing an SMC during FN (OR, 7.87; 95% CI, 0.89-69.7; P = .065) ( Table 4) , whereas very low MBL and MASP-2 were not. In particular, MBL was normal in 14 of 16 FN episodes with SMC (3 of 3 with death, 12 of 13 with PICU, 10 of 12 with potentially life-threatening complication), and MBL was low in 1 of 16 FN episodes with SMC (0 of 3 with death, 1 of 13 with PICU, and 1 of 12 with potentially life-threatening complication).
This finding was confirmed in multivariate analysis, adjusted for 4 characteristics known to be associated with SMC (diagnosis of acute myeloid leukemia, interval since chemotherapy 7 days, general condition severely reduced, hemoglobin level 90 g/L) [29] . Here, normal versus low MBL was associated with just a significantly increased risk to develop SMC (multivariate OR, 12.8; 95% CI, 1.01-163; P = .050) ( Table 4) . 
DISCUSSION
In this study, MBL and MASP-2 serum concentrations, taken at diagnosis from pediatric patients with cancer, were not associated with the risk of developing any AEs or bacteremia, when these patients later presented with FN during chemotherapy. However, a normal (1000 ng/mL) versus a low (100-999 ng/mL) MBL serum concentration was significantly and independently associated with an increased risk of an SMC, ie, death, a condition requiring PICU admission, or a potentially lifethreatening complication. Regarding MBL, these results are in line with those of a prospective single-center study on MBL genotype and phenotype (serum concentration at diagnosis and during FN) in 110 children with cancer, 66 of whom experienced FN [20] . MBL genotype and phenotype was not found to be associated with the risk of developing FN or with different parameters of infection during FN. However, MBL-sufficient (>1000 ng/mL) patients, as determined at presentation with FN, had a higher risk of PICU admittance. These findings support the hypothesis that the very large interindividual variations of MBL serum concentrations in healthy subjects and the high frequency of polymorphisms in the MBL2 gene and its promoter reflect that normal versus low MBL may be detrimental in certain situations [8] . This result has been shown for ischemia-reperfusion injury of the heart [32] , kidney [33, 34] , and cerebrum [35] , and is shown here for FN.
Replacement of MBL in MBL-deficient persons has been reported since 1998 in case studies and in phase I studies, using either purified MBL from human plasma or recombinant MBL protein [8, 36] . MBL replacement in a phase II study in 12 MBL-deficient children with cancer was reported to be safe and efficient to restore opsonophagocytosis, whereas no results on the clinical outcome of these children have been reported so far [37, 38] . The results of the present study are in line with published results [20] . Together with contradictory results on the association of MBL deficiency with the risk to develop FN during chemotherapy [12, 13, 16, 17, 19, 20] , they advise against the use of MBL in MBL-deficient children with cancer [8, 21] . This is the first study to evaluate an association of MASP-2 with the risk of developing AE during FN. An indirect comparison is possible with the results of a retrospective single-center study of 94 pediatric patients with cancer who experienced 177 FN episodes [15] . In that study, MASP-2 deficiency (<200 ng/mL) was associated with an increased risk of developing FN during chemotherapy, specifically with FN without microbiologically identified etiology, but not with FN with bacteremia, or with severe bacterial infection. Therefore, these results do not contradict the results of this study.
The main strengths of this study include the following: the broad spectrum of pediatric malignancies incorporated; the multicenter design of the study, which resulted in an adequate number of patients and FN episodes; and the prospective assessment of clearly defined clinical outcomes. The statistical method applied, ie, mixed logistic regression, is exactly suited to the analysis of binary outcomes in repeated instances per patient.
The main limitation of the study results from the fact that MBL and MASP-2 had not been determined prospectively. Some patients had to be excluded because no serum remnants could be found. However, more than three-quarters of potentially eligible patients with FN episodes were finally included. The fact that diagnosis was associated with the probability of inclusion versus exclusion may have slightly distorted the results regarding AE and bacteremia, because diagnosis (specifically, acute myeloid leukemia) was independently associated with these outcomes. A second limitation results from the wide definition used here for AE. This definition may restrict the applicability of these results in clinical and research settings that use narrower definitions. Finally, the reported CIs of some results were quite wide, reflecting the limited study size despite the multicenter design. Thus, some of the questions remain open, both for the group of pediatric patients with cancer as a whole and for subgroups with specific diagnoses.
In conclusion, MBL and MASP-2 serum concentrations in pediatric patients with cancer were not associated with the risk of developing AE or bacteremia during FN. However, normal versus low MBL serum concentrations were associated with an increased risk of SMC during FN. This finding, in line with the results of an earlier single-center study [20] , does not support the concept of MBL supplementation in MBL-deficient children with cancer presenting with FN.
